ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2731

Decomposition Analysis of Spending and Price Trends for Biologic Anti-Rheumatic Drugs in Medicare and Medicaid

Natalie McCormick1, Zachary Wallace 2, Chana Sacks 3, John Hsu 4 and Hyon K. Choi 5, 1Massachusetts General Hospital and Harvard Medical School, Boston, MA, 2Massachusetts General Hospital, Boston, 3Department of General Internal Medicine, Massachusetts General Hospital; Department of Medicine, Harvard Medical School, Boston, MA, 4Mongan Institute, Massachusetts General Hospital; Department of Health Care Policy, Harvard Medical School, Boston, MA, 5Massachusetts General Hospital, Boston, MA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Biologic drugs, cost, Cost containment, economics and healthcare policy

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: 5T047: Plenary III (2727–2732)

Session Type: Plenary Session III

Session Time: 11:00AM-12:30PM

Background/Purpose: Billions of public dollars are spent each year on biologic disease-modifying anti-rheumatic drugs (bDMARDs), but the drivers of bDMARD spending and per-patient cost increases are unclear. We characterized changes in total spending and unit-prices for bDMARDs in Medicare and Medicaid and quantified the major sources of spending increases for public programs and beneficiaries.

Methods: Data Source and Measures: We accessed Medicare Parts B & D and Medicaid drug spending data for years 2012-2016.  These contained aggregated prescription claims for all beneficiaries enrolled in Medicare Parts B (fee-for-service) or Part D (stand-alone or Medicare Advantage plans) or Medicaid.  All bDMARDs with FDA approval for ≥ 1 rheumatic disease through Dec. 2014 were included.  For each bDMARD and calendar-year we extracted total annual spending, and number of recipients, claims, and doses dispensed, and calculated drug unit-price (average cost/dose).  

Statistical Analysis: We calculated five-year changes in total spending and unit-prices for each bDMARD and in-aggregate, after adjusting for general inflation to 2016 dollars.  We then performed standard decomposition analyses to isolate the contributions of four sources of spending growth (drug prices, uptake [number of recipients], treatment intensity [mean # of doses per-claim], and annual # of claims per-recipient) for each bDMARD.  We conducted our analysis including statutory Medicaid rebates (as these decrease public spending), and both excluding and including Medicare rebates (as these are paid by manufacturers to Pharmacy Benefit Managers and Part D plans).  We used time-varying rebates reported by the Congressional Budget Office.

Results: From 2012-2016, annual spending on the 11 included bDMARDs by US public programs and beneficiaries nearly doubled (from $5.3 to $10.3 billion); drug prices increased by a mean of 52% in Part D and just 20% in Part B (Table).  Controlling for general inflation, unit-price increases alone accounted for 56% ($1.7 billion) of the five-year, $3.0 billion spending increase within Part D (Figure); increased uptake accounted for 37% ($1.1 billion).  After accounting for time-varying rebates, price hikes were still responsible for 53% ($1.4 billion) of the Part D spending increase.  Adalimumab and etanercept, two of the oldest bDMARDs, were prescribed to the largest numbers of Part D beneficiaries and had the biggest unit-price increases: 84% and 88%, respectively.  Medicaid spending and price trends were similar to Part D (Figure).

Majority of spending growth for the oldest Part B drugs (rituximab, abatacept, and infliximab) was from price increases (72-88%), while for the five newer drugs (golimumab, ustekinumab, tocilizumab, certolizumab, and belimumab), number of recipients was the main driver (63-81% of spending growth).

Conclusion: Post-market drug-price changes alone accounted for the majority of recent bDMARD spending growth, and manufacturers’ rebates had little impact on these findings.  Beyond rebates, policy interventions that target price increases, particularly under Part D plans, may help mitigate public-payer drug spending and out-of-pocket costs for the elderly and disabled beneficiaries who rely on bDMARDs.


acr2019 bdmard cost abstract table

Spending and Uptake for Biologic DMARDs Covered under Medicare Parts D and B -drugs ranked by 2016 spending-

Component proportion of Biologic DMARD spending increases from 2012 to 2016, by public program -drugs ranked by 2016 spending, $ millions-


Disclosure: N. McCormick, None; Z. Wallace, National Institute of Arthritis, Musculoskeletal, and Skin Diseases, 2, Rheumatology Research Foundation, 2; C. Sacks, None; J. Hsu, None; H. Choi, AstraZeneca, 2, GSK, 5, Horizon, 5, Selecta, 5, Takeda, 5.

To cite this abstract in AMA style:

McCormick N, Wallace Z, Sacks C, Hsu J, Choi H. Decomposition Analysis of Spending and Price Trends for Biologic Anti-Rheumatic Drugs in Medicare and Medicaid [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/decomposition-analysis-of-spending-and-price-trends-for-biologic-anti-rheumatic-drugs-in-medicare-and-medicaid/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/decomposition-analysis-of-spending-and-price-trends-for-biologic-anti-rheumatic-drugs-in-medicare-and-medicaid/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology